急性呼吸窘迫综合征的研究现状

急性呼吸窘迫综合征(ARDS)是多种原发病引起的急性进行性、低氧性呼吸衰竭,病死率较高,发病机制复杂,目前没有明确的诊断标准,多参考美国欧洲ARDS共识(AECC)。肺动脉楔压监测、胸部CT、正电子发射断层扫描以及肺泡灌洗液等被应用于ARDS的诊断,本病治疗包括针对不同炎症阶段进行抗炎性反应、减少肺血管损伤、抗肺的氧化损伤、促进肺泡液体的清除和机械通气技术策略的改进等,间充质干细胞及其他药物,如他汀类、胰岛素和β干扰素目前也在临床试验中,其效果令人期待。

The Research Status of Acute Respiratory Distress Syndrome

Acute respiratory distress syndrome （ARDS） is progressive respiratory failure due to some primary diseases with high mortality and complicated pathogenesis. There is no definite diagnostic criteria currently for ARDS, mostly referring to the American-European Conference （AECC）. Pulmonary artery wedge pressure, chest CT scanning, positron emission tomography technique, arid bronchoalveolar lavage are used to diagnose ARDS. Therapy advancement includes anti-inflammation, preventing pulmonary vascular injury, antioxidation, promoting lung liquid clearing, and mechanical ventilation strategy improving at different stages. Mesenchymal stern cell and others drug such as statins, insulin, and interferon β are also currently under clinical trials ,with promising consequences.